坎妥珠單抗

维基媒体消歧义页

坎妥珠單抗INN:cantuzumab),也稱huC242,是一種單株抗體,設計用於治療癌症。它結合CanAg抗原。[1]

它通常與幾種細胞毒性劑之一連接,產生抗體藥物偶聯物英語Antibody–drug conjugate

靶向CanAg

"HuC242與腫瘤相關碳水化合物抗原CanAg(MUC1的一種新型糖型)的胞外結構域結合。CanAg在大多數胰腺癌膽道癌結直腸癌中強烈表達。它還在相當大比例的胃癌(55%)、子宮癌(45%)、非小細胞肺癌(40%)和膀胱癌(40%)中表達。"[2]

參考資料

  1. ^ Rodon, J; Garrison, M; Hammond, LA; de Bono, J; Smith, L; Forero, L; Hao, D; Takimoto, C; Lambert, JM; Pandite, L; Howard, M; Xie, H; Tolcher, AW. Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study. Cancer Chemother Pharmacol. 2008, 62 (5): 911–9. PMID 18301896. S2CID 5829870. doi:10.1007/s00280-007-0672-8. 
  2. ^ A Phase I Study of Cantuzumab Mertansine Administered as a Single Intravenous Infusion Once Weekly in Patients with Advanced Solid Tumors. Helft et al. 2004. [2024-03-06]. (原始內容存檔於2016-01-19).